Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.
A new Yale Cancer Center study finds a targeted diet and exercise intervention could improve outcomes for women undergoing chemotherapy for breast cancer.
The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
New NCCN Guidelines for Patients: Blood Clots and Cancer provides much-needed education about recognizing and preventing the rarely-discussed cancer-associated consequence that is a major cause of death and morbidity
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise.
New study in JNCCN from the University of Michigan found English speakers who call a hospital general information line were able to get information on next steps to access cancer care 94% of the time, compared to 38% for Spanish speakers and just 28% for Mandarin speakers.
By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero.
MD Anderson and Panacea Venture announced the launch of Manaolana Oncology, a new company created to develop and advance antibody-based therapies against novel cancer targets.
UC Davis and the University of Oxford researchers developed a new software tool, SparkMaster 2, that allows scientists to analyze normal and abnormal calcium activity in cells. Problems with how and when calcium is released by cells can have an impact on a range of diseases, including arrhythmia and hypertension.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel computational tool to detect single base pair DNA changes in single-cell sequencing data, a potential target to treat hypertension caused by drugs commonly used in organ transplants, further insights into the steps involved in genetic recombination, a novel treatment target for a subset of adenoid cystic carcinoma (ACC), a combination therapy that improves outcomes in certain patients with acute myeloid leukemia (AML), and a target for treating prolonged cytopenia in patients with relapsed/refractory large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapy.
The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD, PhD, and Julien Dilly, MS, research grants of $250,000 and $150,000, respectively over a 2-year period, to support their crucial work in the field of pancreatic cancer research.
UC Davis MIND Institute Director Leonard Abbeduto has co-authored a paper in the American Journal on Intellectual and Developmental Disabilities that calls for a paradigm shift in disability research.
Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD. Wet AMD is a leading cause of vision loss among older adults. Glenn Yiu, a professor of ophthalmology at UC Davis Health, is the principal investigator for the new clinical trial.
The National Comprehensive Cancer Network’s Oncology Research Program selects projects focused on reducing gaps in patient care for people with limited-stage (LS) and extensive stage (ES) small cell lung cancer.
Gene therapy with microRNA-22 produced better survival outcomes than the current FDA-approved drug for liver cancer and without noticeable toxicity in new mouse study.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
The National Comprehensive Cancer Network (NCCN)—a not-for-profit alliance of leading academic cancer centers—announces Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO), replacing the retiring longtime CEO, Robert W. Carlson, MD.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.
Can your child see the blackboard at school? Ophthalmologist Marcela Maria Estrada explains why kids often don’t know they have bad eyesight and gives tips for healthy vision.
The Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center is expanding its viral infection research in Africa. The cancer center has received a $5.5 million, five-year specialized research center grant (U54CA277834) from the National Cancer Institute to investigate virus-associated tumors that disproportionately impact men and women living with HIV in sub-Saharan Africa.
The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of physical activity programs for survivors, the dissemination of targeted tobacco cessation programs and the recruitment of a first-time, tenure-track faculty member.
Joann B. Sweasy, PhD, has been elected to serve as vice president/president-elect of AACI’s Board of Directors. Three new board members were also chosen: Edward Chu, MD, MMS; Raymond N. DuBois, MD, PhD; and Yolanda Sanchez, PhD.
The National Comprehensive Cancer Network expands materials tailored for the MENA region to help improve patient outcomes by standardizing local cancer care; includes new adaptation focused on genetic/familial cancer risk, as well as care for ovarian/fallopian tube/primary peritoneal cancers.
In a new study published and included on the cover of the journal Cancer Research, Moffitt Cancer Center researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient outcomes.
The Food and Drug Administration announced yesterday the approval of HEPZATO Kit to treat ocular melanoma that has spread to the liver. HEPZATO uses a hepatic delivery system to inject the chemotherapy drug melphalan into the liver, a procedure referred to as percutaneous hepatic perfusion (PHP). Moffitt Cancer Center’s Jonathan S. Zager, M.D., was the lead international principal investigator on the multinational FOCUS phase 3 clinical trial to test the procedure, which is manufactured by Delcath Systems, Inc.
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative to accelerate and expand UT Austin’s burgeoning medical district into a world-class academic medical center for education, research and patient care. The University of Texas at Austin Medical Center will start with two new hospital towers -- The University of Texas MD Anderson Cancer Center and a UT Austin hospital. MD Anderson, the nation’s #1 cancer hospital, will expand its Houston footprint to Austin by building and operating a new, comprehensive cancer center, while UT Austin will build and operate its new specialty hospital.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Adrienne Phillips, MD, MPH, as director of Cell Therapy and Bone Marrow Transplantation Northern Regions at New Jersey’s leading cancer program and only National Cancer Institute (NCI)- Designated Comprehensive Cancer Center.
Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS), together with other collaborating groups, have discovered the first lipid vascular ‘ZIP code’ in the lungs, with implications for improved diagnostics and treatments, including patients with severe human respiratory diseases such as emphysema, COVID-19, COPD and lung cancer.
Penile squamous cell carcinoma is a rare form of penile cancer with limited treatment options. An international study led by Yale Cancer Center researchers at Yale School of Medicine finds that the use of immune checkpoint inhibitors (ICIs) offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Niketa C. Shah, MD, as chief of Pediatric Bone Marrow Transplantation and Cellular Therapies at New Jersey’s leading cancer program.
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced new grants awarded to improve quality initiatives focused on optimizing biomarker-directed therapy in metastatic colorectal cancer.
Breast cancer screening for women over 70 is not without risks, according to new research from Yale School of Medicine’s COPPER Center. Although some guidelines recommend continuing screening for older women, a new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
JNCCN study sheds light on a rapid shift in practice evolution by oncologists treating people with colon cancer adjuvantly after primary surgery, following publications from the IDEA collaboration.
Damon Reed, MD, has joined Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Head of the Division of Pediatric Solid Tumors and as Chief of the Pediatric Sarcoma Service.
The New Mexico Cancer Care Alliance (NMCCA) has rebranded as the New Mexico Cancer Research Alliance (NMCRA) to strengthen its focus on delivering cancer clinical trials to New Mexicans. Through the NMCRA’s unique collaboration, every New Mexican has access to cancer clinical trials. Cancer clinical trials test new treatments and new methods of delivering and improving cancer care.
One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.
Researchers at Dana-Farber Cancer Institute have created an AI-based tool that uses tumor gene sequencing data to predict the primary source of a patient’s cancer. The study, published in in Nature Medicine, suggests that this predictive tool, called OncoNPC, could help guide treatment of cancer and improve outcomes in difficult to diagnose cases.
A Ludwig Cancer Research study has identified a pair of genes whose expression by a type of immune cell within tumors is predictive of outcomes for cancer patients and is linked to a vast network of gene expression programs, engaged by multiple cell types in the tumor microenvironment, that control human cancers.
Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor receptor (EGFR) mutations are found in a significant proportion of lung adenocarcinomas, and the use of tyrosine kinase inhibitors (TKIs) such as osimertinib, have improved patient outcomes.
The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search. His appointment is effective Sept. 1.
Smilow Cancer Hospital at Yale New Haven is ranked as one of the highest hospitals for cancer care in the country by U.S. News & World Report. This year, Smilow Cancer Hospital at Yale New Haven is listed in the top 50 in the nation and is number 1 in Connecticut. "We are proud to be recognized as one of the leading cancer hospitals in our country,” said Eric Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise. Dr. Trang VoPham is an epidemiologist focusing on environmental exposures and risk, follow her on social media.
Memorial Sloan Kettering Cancer Center has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.